Treatment of small cell lung cancer with a parp inhibitor
AssigneeMedivation Technologies, Inc.
InventorsYing FENG, Leonard E. POST, Yuqiao SHEN, Yuanbin RU, Evelyn WANG, Karen YU
Life of this patent
Estimating the term…
Abstract
Described are methods of treatment of a small cell lung cancer subject expressing Schlafen-11 (SLFN 11) with a Poly (ADP-ribose) polymerases (PARP) inhibitor or a pharmaceutically acceptable salt thereof. Specifically, the method comprising detecting SLFN 11 in a tumor cell sample from the subject, and administering effective amount of a PARP inhibitor, such as talazoparib or the tosylate salt of talazoparib, to the subject.
Claims23
A method of treating small cell lung cancer in a subject expressing SLFN11, comprising administering to the subject an effective amount of a PARP inhibitor.
A method of treating a small cell lung cancer subject, comprising detecting one or more of SLFN11, SIL1, SLC25A3, MAF, AP3B1, C1orf50, BCL2, DDX6, or GULP1, in a tumor cell sample from the subject, and administering an effective amount of a PARP inhibitor to the subject.
A method of selecting a small cell lung cancer subject for PARP inhibitor chemotherapy, comprising detecting one or more of SLFN11, SIL1, SLC25A3, MAF, AP3B1, C1orf50, BCL2, DDX6, and GULP1, in a small cell lung cancer tumor sample of the subject, and administering an effective amount of a PARP inhibitor to the subject.
A method of treating small cell lung cancer in a subject expressing SLFN11, comprising administering to the subject an effective amount of talazoparib or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.